Biotech RadarJobs updated

COMPANY

Sparrow Pharmaceuticals

HQ: Boston, MA source · sparrowpharma.com ↗

Clinical Phase 2

Keywords: metabolic type 2 diabetes mellitus Cortisol Excess Polymyalgia Rheumatica Autonomous Cortisol Secretion ACTH-Independent Cushing Syndrome ACTH-Independent Adrenal Cushing Syndrome, Somatic Moderate Renal Impairment Cushing's Syndrome I Cushing Disease Due to Increased ACTH Secretion Cortisol Overproduction Ectopic ACTH Secretion Type 2 Diabetes Mellitus in Obese Obesity Type2Diabetes SPI-62 clofutriben SPI-62 dose

Location: Boston, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

$95.0MRaised (2 yrs)8Trials (company is sponsor)

Raises and deals from press releases

Raises announced in these releases: $95M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

  1. Trial start Phase 1: Clofutriben Pharmacokinetics in Patients With Impaired Renal Function source ↗
  2. Trial start Phase 2: Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) source ↗
  3. Trial start Phase 1: Pharmacokinetic Interaction Trial of Clofutriben With Midazolam and Prednisolone source ↗
  4. Raise Private equity round — Series B: $95M (total, as published), announced Sep 24, 2025. Source: company release on GlobeNewswire. source ↗
  5. Raise Series B · $95M source ↗
  6. Trial start Phase 2: SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor source ↗
  7. Trial start Phase 2: SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome source ↗
  8. Trial start Phase 2: A Trial of Prednisolone in Combination With SPI-62 or Placebo in Subjects With Polymyalgia Rheumatica (PMR) source ↗
  9. Trial start Phase 1: A Trial of Prednisolone in Combination With SPI-62 in Participants With Polymyalgia Rheumatica (PMR) source ↗
  10. Trial start Phase 1: A Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62 source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $95.0M. Last 2 years.

Clinical trials (lead sponsor) 8

RecordTitlePhaseStatusStartPrimary completion
NCT07296484Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)Phase 2RecruitingNov 29, 2025Dec 31, 2027 (estimated)
NCT07226635Pharmacokinetic Interaction Trial of Clofutriben With Midazolam and PrednisolonePhase 1CompletedOct 3, 2025Dec 16, 2025 (actual)
NCT05436639SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal TumorPhase 2CompletedJul 1, 2023Dec 1, 2024 (actual)
NCT07227922Clofutriben Pharmacokinetics in Patients With Impaired Renal FunctionPhase 1RecruitingNov 30, 2025Apr 30, 2026 (estimated)
NCT05307328SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's SyndromePhase 2CompletedSep 1, 2022Aug 1, 2025 (actual)
NCT06281236A Trial of Prednisolone in Combination With SPI-62 in Participants With Polymyalgia Rheumatica (PMR)Phase 1TerminatedFeb 22, 2022Mar 25, 2025 (actual)
NCT05436652A Trial of Prednisolone in Combination With SPI-62 or Placebo in Subjects With Polymyalgia Rheumatica (PMR)Phase 2CompletedJul 22, 2022Apr 25, 2025 (actual)
NCT05409027A Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62Phase 1CompletedJul 23, 2021Mar 10, 2022 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback